Advanced Tissue Sciences Inc. finalized its agreement toacquire privately held Neomorphics Inc. The acquisition,scheduled to close by Oct. 31, was originally announced inMarch.
As previously reported, all of Neomorphics' stock is to beexchanged for ATS common stock (NASDAQ:ATIS) valued at$21 million. ATS stock closed Wednesday at $10.63, up 13cents.
Neomorphics of Lexington, Mass., is developing technology toengineer human tissue and organ transplants and advancedbiomaterials.
ATS of La Jolla, Calif.,is developing systems to grow humantissue and organs, including skin, cartilage, oral mucosa, bonemarrow and liver, for potential therapeutic and laboratoryapplications.
(c) 1997 American Health Consultants. All rights reserved.